CTNNB1 and hepatocellular carcinoma: Foundation Medicine testing revealed the p.G34V variant in CTNNB1, previously reported in hepatocellular carcinoma as an activating mutation.26 Comparative RNA-Seq analysis of the liver sample (TH03_0004_S04) uncovered gene expression similar to the proliferation subtype of hepatocellular carcinoma27,28 as well as outlier expression of HSP90B1, interleukin 6, and 4 other members of the JAK/STAT pathway.